- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Maze Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| Mi | Maze Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.01. | Maze Therapeutics stock price target reiterated at $60 by H.C. Wainwright | 3 | Investing.com | ||
| 19.12.25 | Guggenheim raises Maze Therapeutics stock price target to $46 on CKD program | 1 | Investing.com | ||
| 18.12.25 | Leerink Partners raises Maze Therapeutics stock price target to $50 on AMKD study | 2 | Investing.com | ||
| 18.12.25 | Maze Therapeutics: Leerink Partners hebt Kursziel vor wichtigen Studiendaten auf 50 US-Dollar an | 10 | Investing.com Deutsch | ||
| MAZE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 04.12.25 | H.C. Wainwright hebt Kursziel für Maze Therapeutics auf 60 US-Dollar an | 9 | Investing.com Deutsch | ||
| 04.12.25 | Maze Therapeutics stock rating initiated at Overweight by Wells Fargo | 4 | Investing.com | ||
| 13.11.25 | Raymond James startet Coverage für Maze Therapeutics mit "Outperform" | 7 | Investing.com Deutsch | ||
| 13.11.25 | Raymond James initiates Maze Therapeutics stock with Outperform rating | 3 | Investing.com | ||
| 06.11.25 | Maze Therapeutics, Inc.: Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights | 150 | GlobeNewswire (Europe) | First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected... ► Artikel lesen | |
| 06.11.25 | Maze Therapeutics to present data on kidney disease therapies at ASN meeting | 9 | Investing.com | ||
| 17.10.25 | Maze Therapeutics files to sell 9.23M shares of common stock for holders | 2 | Seeking Alpha | ||
| 17.10.25 | Maze Therapeutics, Inc. - S-1, General form for registration of securities | 2 | SEC Filings | ||
| 06.10.25 | Maze Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 06.10.25 | Maze Therapeutics appoints Hervé Hoppenot as board chairman | 10 | Investing.com | ||
| 06.10.25 | Maze Therapeutics, Inc.: Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors | 224 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for... ► Artikel lesen | |
| 03.10.25 | Maze Therapeutics stock rating reiterated at Buy by H.C. Wainwright | 1 | Investing.com | ||
| 03.10.25 | Maze Therapeutics: H.C. Wainwright bestätigt "Buy"-Rating und sieht deutliches Aufwärtspotenzial | 4 | Investing.com Deutsch | ||
| 19.09.25 | Maze Therapeutics, Inc. (MAZE): A Bull Case Theory | 18 | Insider Monkey |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABIVAX | 98,30 | -0,30 % | ABIVAX Société Anonyme (ABVX): A Bull Case Theory | ||
| CYTOKINETICS | 52,50 | -0,94 % | Cytokinetics stock maintains Buy rating at B.Riley amid strong CMI market | ||
| CYTOMX THERAPEUTICS | 4,826 | +0,88 % | SD-Tipp CytomX: Was tun nach +1.438% in 10 Monaten? | Unsere Aktien-Empfehlung CytomX Therapeutics erlebt derzeit einen außergewöhnlich starken Kursverlauf. Innerhalb kurzer Zeit hat sich das Papier von einem lange übersehenen Small-Cap-Titel zu einem... ► Artikel lesen | |
| UNIQURE | 21,780 | +0,32 % | uniQure Inc.: uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in a-Gal A Enzyme Activity in Patients with Fabry Disease | ~ Supraphysiological expression of a-Gal A activity maintained for over a year in longest treated patient as of data cutoff date ~
~ Stable Lyso-Gb3 levels maintained post-dosing, regardless of... ► Artikel lesen | |
| PALISADE BIO | 1,660 | +10,67 % | Palisade Bio, Inc.: Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board | Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade... ► Artikel lesen | |
| TENAX THERAPEUTICS | 2,770 | -100,00 % | Tenax Therapeutics, Inc.: Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026 | ||
| AMYLYX PHARMACEUTICALS | 13,980 | +7,62 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| NURIX THERAPEUTICS | 16,850 | +5,64 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update | First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile... ► Artikel lesen | |
| CELCUITY | 91,50 | +1,10 % | Wolfe Research recommends buying Celcuity stock on weakness related to external catalyst | ||
| TREVI THERAPEUTICS | 11,450 | +4,66 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer | Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth
NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics... ► Artikel lesen | |
| PEPGEN | 4,465 | +4,08 % | PepGen Inc.: PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society | PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and... ► Artikel lesen | |
| ALUMIS | 26,160 | -0,68 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | Qiagen übertrifft Markterwartungen im vierten Quartal | DJ Qiagen übertrifft Markterwartungen im vierten Quartal
DOW JONES--Qiagen hat im Schlussquartal 2025 den Umsatz gesteigert, der operative Gewinn ging gegenüber dem Vorjahr zurück. 2026 rechnet... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report |
MAZE THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +1,150 (+2,62 %) liegt der Kurs bei 45,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAZE THERAPEUTICS INC finden Sie auf Wallstreet Online.